Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia single ascending dose controlled trial of AEM 28 in patients with elevated cholesterol levels.

Trial Profile

Phase Ia single ascending dose controlled trial of AEM 28 in patients with elevated cholesterol levels.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AEM 28 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; First in man
  • Sponsors Capstone Therapeutics; LipimetiX

Most Recent Events

  • 02 Sep 2014 Status changed from `recruiting' to `completed', as reported by a Capstone Therapeutics media release.
  • 02 Sep 2014 Interim results published in a Capstone Therapeutics media release.
  • 09 Apr 2014 Dosing has been initiated, according to a media release from LipimetiX and Capstone Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top